TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$500 Million

Madrigal Pharmaceuticals

Follow-on Offering

Bookrunner, September 2023

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver.